Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
131 results about "Campylobacter" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Campylobacter (meaning "curved bacteria") is a genus of Gram-negative bacteria. Campylobacter typically appear comma- or s-shaped, and are motile. Most Campylobacter species can infect humans and other animals, causing disease. The bacterium's main natural reservoir is poultry; humans can contract the disease from eating food contaminated with Campylobacter species. Another source of infection is contact with infected animals, which often carry Campylobacter asymptomatically. At least a dozen species of Campylobacter have been implicated in human disease, with C. jejuni and C. coli being the most common. C. jejuni is now recognized as one of the main causes of bacterial foodborne disease in many developed countries. C. jejuni infection can also spread to the blood in individuals with AIDS, while C. lari is a known cause of recurrent diarrhea in children. C. fetus is a cause of spontaneous abortions in cattle and sheep, as well as an opportunistic pathogen in humans. This genus has been found to be part of the salivary microbiome.
Mammalian animal composition
InactiveUS7427398B2Avoid loweringReduces and prevents riskBiocideBacteriaMicroorganismGenus Campylobacter
The present invention relates to the use of probiotic microorganism in the manufacture of a composition for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal. It also relates to a method for the prevention or reduction of gastrointestinal Campylobacter infection in a mammalian animal, the method comprising administering to said animal, a probiotic microorganism. The invention also relates to a probiotic microorganism, for use in preventing or reducing gastrointestinal Campylobacter infection in a mammalian animal.
Owner:MARS INC
Campylobacter glycans and glycopeptides
ActiveUS20060165728A1Prevent groundwater pollutionEliminating and reducing presenceAntibacterial agentsImmunoglobulins against bacteriaMagic angle spinningGlycopeptide
Multiple strains and species of Campylobacter were found to share a common glycan moitie which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1,4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2,4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.
Owner:NAT RES COUNCIL OF CANADA
Oligonucleotide probe kit for detecting common intestine trac kpathogenic bacteria and its use
InactiveCN1683565AQuick checkAccurate detectionMicrobiological testing/measurementAgainst vector-borne diseasesAntigenBio engineering
The present invention belongs to the field of microbe detecting technology. The oligonucleotide probe for detecting common intestinal tract pathogenic bacteria is designed on 16S rRNA and 23S rRNA of bacteria, ipaH of dysentery bacillus giant plasmid, VipR of Salmonella typhi and other gene sequence, has length of 25-50 bp, and relatively high sensitivity and specificity. The oligonucleotide probe is suitable for detection based on nucleic acid hybridization principle, especially detection based on gene chip principle. Under certain use condition, it can detect Listeria, parahemolutic vibrio, Campylobacter, etc. It may be used in many aspects, such as disease diagnosis, environment detection, food poisoning detection, etc.
Owner:RADIOLOGY INST ACAD OF MILITARY MEDICINE SCI PLA
Cytolethal Distending Toxins and Detection of Campylobacter Bacteria Using the Same as a Target
ActiveUS20070212691A1Quick checkRapid and convenient determinationBacteriaImmunoglobulins against bacteriaTypingCytolethal distending toxin
The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.
Owner:FUSO PHARMA INDS
Detection of bacterium by utilizing dnaj gene and use thereof
InactiveCN101558168AMicrobiological testing/measurementRecombinant DNA-technologyBacteroidesStaphylococcus species
Disclosed is a method for detecting the species of a bacterium in a simple manner. Specifically disclosed is a method for detecting the species of a bacterium, which can detect at least one bacterial species selected from Staphylococcus species, Streptococcus species, Klebsiella species, Escherichia species, Mycobacterium species, Legionella species, Vibrio species, Bacillus species, Neisseria species, Campylobacter species, Chlamydia species, Chlamydophila species, Mycoplasma species, Listeria species, Salmonella species and Yersinia species, and which comprises the steps of: a) contacting a sample suspected to contain a nucleic acid derived from the bacterium species to be detected with a nucleic acid molecule capable of hybridizing with at least a part of a DnaJ gene derived from the bacterial species; and b) detecting the presence or absence of the hybridization between the nucleic acid molecule and the nucleic acid contained in the sample.
Owner:GIFU UNIVERSITY +1
Application of Harmine derivative to preparation of antibacterial medicine
The invention discloses application of a Harmine derivative to preparation of antibacterial medicines. The bacteria is selected from Acinetobacter, Bacillus, Campylobacter, Chlamydia, Chlamydia trachomatis, Clostridium, Citrobacter, Escherichia, enterohemorrhagic escherichia coli, enteric bacteria, Enterococcus, Francisella, Haemophilus, helicobacter, Klebsiella Bacillus, Lester monocytogenes, Moraxella, Mycobacterium, Neisseria, proteus, Pseudomonas, Salmonella, shewanella oneidensis, Shigella, Stenotrophomonas, Staphylococcus, Streptococcus and Yersinia.
Owner:XINJIANG HUASHIDAN PHARMA RES
Methods and compositions including spore-forming bacteria for increasing the health of animals
ActiveUS20130136695A1Good for healthIncrease productionAntibacterial agentsBiocideBacteroidesBiology
Methods, compositions and bacterial isolates for improving the gastrointestinal health of animals and in particular of poultry are provided herein. The methods include administering an endospore-forming bacteria to an animal. The bacteria are selected for the ability to reduce the growth and presence of bacterial pathogens, such as Salmonella, Clostridium, and Campylobacter, in the gastrointestinal tract of the animal. The bacteria are also selected for the ability to improve at least one production parameter in the animal.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
Antibodies against flagellin and uses thereof
The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating infections and diseases using anti-flagellin antibodies in humans, other animals and birds.
Owner:INOTECK PHARMA CORP
Combinant polypeptide for use in the manufacture of vaccines against Campylobacter induced diarrhea and to reduce colonization
This invention comprises a recombinant protein comprising the maltose binding protein (MBP) of Escherichia coli fused to amino acids 5–337 of the FlaA flagellin of Campylobacter coli VC167 which has provided evidence of immunogenicity and protective efficacy against challenge by a heterologous strain of campylobacter, Campylobacter jejuni 81–176 in mammals. The invention further comprises a recombinant DNA construct encoding the immunodominant region (region I through III) of flagellin from Campylobacter spp. for use as a component of a vaccine against Campylobacter diarrhea. The invention therefore represents an effective treatment against Campylobacter but avoids inducing the autoimmune Guillain Barre Syndrome (GBS), a post-infection polyneuropathy caused by Campylobacter molecular mimicry of human gangliosides which has hampered the development of vaccines heretofore.
Owner:THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY
Methods for specific rapid detection of pathogenic food-relevant bacteria
InactiveUS20050123946A1Sugar derivativesMicrobiological testing/measurementBacteroidesStaphylococcus aureus
The invention relates to a method for the detection of pathogenic food-relevant bacteria, particularly to a method for the simultaneous specific detection of bacteria of the genus Listeria and the species Listeria monocytogenes by in situ-hybridization as well as to a method for the specific detection of bacteria of the species Staphylococcus aureus by in situ-hybridization as well as to a method for the specific detection of bacteria of the genus Campylobacter and the species C. coli and C. jejuni by in situ-hybridization as well as the corresponding oligonucleotide probes and kits, with which the inventive methods may be carried out.
Owner:VERMICON
One-step multiplex pcr for the identifiation and differentiation of campylobacter species
InactiveUS20060051752A1Sugar derivativesMicrobiological testing/measurementPcr assayBacterial isolate
Described herein are a plurality of primers which may be used in a multiplex PCR assay in a fast, accurate, reliable and specific fashion for detecting the presence of specific Campylobacter strains within a sample. These kits can be used on bacterial isolates and has the potential for use directly on foods and environmental samples.
Owner:HER MAJESTY THE QUEEN & RIGHT OF CANADA REPRESENTED BY THE MIN OF HEALTH
Antibodies against flagellin and uses thereof
Owner:YEDA RES & DEV CO LTD +1
Methods and compositions including spore-forming bacteria for increasing the health of animals
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ARKANSAS
Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof
The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and / or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.
Owner:ETH ZZURICH
Nontoxic killer of E. coli and other problem microorganisms
Owner:MARVEL TECH USA
Cytolethal distending toxins and detection of Campylobacter bacteria using the same as a target
ActiveUS7563594B2Quick checkRapid and convenient determinationBacteriaTissue cultureEscherichia coliTyping
The present inventors succeeded in cloning the CDT genes of C. coli and C. fetus, which were previously unknown, and in determining their sequences. In addition, the inventors also developed specific primers and primers common to the two species by comparing the CDTs of C. jejuni and C. fetus. Furthermore, the inventors demonstrated that these primers were applicable to multiplex PCR that simultaneously allows for the rapid and convenient determination of the presence of Campylobacter CDT and identification of species, and that they can also be used in PCR-RFLP-based typing.
Owner:FUSO PHARMA INDS
Use of an enzyme for the manufacture of an agent for controlling bacterial infection
InactiveUS20060083731A1Advantage for human healthLess harmful to the environmentAntibacterial agentsBiocideBacillus perfringensEconomic benefits
Owner:FINNFEEDS INT
Campylobacter immunogenic compositions and uses thereof
ActiveUS9328148B2Reduce colonizationAntibacterial agentsBacterial antigen ingredientsImmunogenicityCampylobacter
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Quaternary ammonium compounds in the treatment of water and as antimicrobial wash
InactiveUS20050250821A1Growth inhibitionLow costBiocideWater/sewage treatment by substance additionEscherichia coliAmmonium compounds
Low levels of quaternary ammonium compounds are effective antimicrobial agents in drinking water and potentiate the antimicrobial power of organic acids used as antimicrobials for such purposes. The method is effective against both Gram (−) and Gram (+) bacteria, including but not limited to, Salmonella sp., E. coli, Campylobacter sp. as Staphylococcus sp. and Listeria sp. The combination of quaternary ammonium compounds and one or more organic acids can also be effectively used as antimicrobial washes for fruits, vegetables, meat, and animal carcasses.
Owner:KEMIN IND INC
Modifications of cst-ii for increased protein expression
The present invention provides modified Campylobacter sialyltransferase proteins that exhibit enhanced expression as compared to its unmodified form. Nucleic acids that encode the sialyltransferase proteins are also included, as are methods to produce and use the sialyltransferase proteins.
Owner:RATIOPHARM GMBH
Campylobacter Jejuni Outer Membrane Protein Immunogenic Composition
InactiveUS20080131453A1Reduce probabilityBacterial antigen ingredientsImmunoglobulins against bacteriaEpitopeMicrobiology
Owner:MEDICAL COLLEGE OF GEORGIA RES INST
Antibacterial Peptide and Method of Treatment Using the Antibacterial Peptide
ActiveUS20170246240A1Treat and prevent bacterial infectionPreventing and delaying onsetPeptide/protein ingredientsFood processingStaphylococcus cohniiStaphylococcus pseudintermedius
A method of treating or preventing a bacterial infection in an animal comprises administering to the animal an effective amount of an antibacterial peptide, the antibacterial peptide being derived from degraded date pits which are degraded by solid state degradation by a fungus, Trichoderma reesei. The antibacterial peptide has a molecular mass of less than 10 kDa and an amino acid sequence including (a) SEQ ID NO:4 or (b) SEQ ID NO:6. The bacterial infection is caused by a Gram-positive bacteria or a Gram-negative bacteria, for example, a Salmonella species, a Campylobacter species, a Shigella species, an Escherichia species, a Pseudomonas species, and a Staphylococcus species.
Owner:UNITED ARAB EMIRATES UNIVERSITY
Campylobacter Pilus Protein, Compositions and Methods
InactiveUS20090285821A1Reduce morbidityAntibacterial agentsBacterial antigen ingredientsImmunogenicityOrganism
The present disclosure provides coding and amino acid sequences for a Campylobacter jejuni pilus protein (and from other species as well). This protein, when administered to a human or animal, elicits the expression of an immune response to Campylobacter jejuni, with the result that colonization and / or infection by this organism is reduced. Recombinant protein or biofilm material comprising the pilus protein is formulated into immunogenic compositions, especially for mucosal administration. Thus, the present invention provides methods for improvement of the microbial quality of food products including poultry, eggs, meat and dairy products, and indirectly of plant foods that may come in contact with agricultural waste, either from fertilization or from irrigation water.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Campylobacter Immunogenic Compositions and Uses Thereof
ActiveUS20150030624A1Stimulate immune responseReduce decreaseAntibacterial agentsBacterial antigen ingredientsImmunogenicityGenus Campylobacter
The present invention provides immunogenic compositions against Campylobacter and methods for using the immunogenic composition to generate an immune response against Campylobacter and / or reduce intestinal colonization by Campylobacter.
Owner:THE ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIV OF ARIZONA
Food-poisoning bacteria detection carrier, and method for detecting food-poisoning bacteria
InactiveCN102844447ABioreactor/fermenter combinationsBiological substance pretreatmentsStaphylococcus cohniiFood poisoning
Owner:TOYO SEIKAN KAISHA LTD +1
Real-time fluorescence quantitative PCR detection method of campylobacter jejuni and kit
ActiveCN101886133AImprove accuracyGood precisionMicrobiological testing/measurementFluorescence/phosphorescenceDiseaseFeces
The invention discloses a real-time fluorescence quantitative PCR detection method of campylobacter jejuni and a kit. In the invention, a primer and a Taqman probe are designed according to a conserved region of a campylobacter jejuni flagellin A (flaA) gene for qualitatively detecting the copy number of nucleic acid of the campylobacter jejuni in a fecal sample of a clinical patient, the fecal samples of a monkey and a dog, and the sample of ileocecal contents of a miniature swine, an upstream primer sequence SEQ ID NO:1, a downstream primer sequence SEQ ID NO:2 and a Taqman probe sequence SEQ ID NO:3. The invention has a great practical significance on quality control of relevant people and animal derived biological products and the inspection and quarantine field of import and export animals, and can ensure the quality of the relevant biological products. The detection method and the kit of the invention can be applied to diagnosis of campylobacter diseases and verification of the campylobacter jejuni in the biological products, thus having wide application prospect.
Owner:NAT INST FOR FOOD & DRUG CONTROL
Campylobacter glycans and glycopeptides
ActiveUS7598354B2Avoid pollutionEliminating and reducing presenceAntibacterial agentsImmunoglobulins against bacteriaMagic angle spinningGlycopeptide
Multiple strains and species of Campylobacter share a common glycan moiety which is present in a plurality of surface-exposed glycoproteins. This glycan has the formula: GalNAc-a1, 4-GalNAc-a1,4-[Glc-β1,3]GalNAc-a1,4-GalNAc-a1,4-GalNAc-a1,3-Bac, wherein Bac is 2, 4-diacetamido-2,4,6-trideoxy-D-glucopyranose. This glycan and immunologically active fragments of it have use as vaccines against campylobacter infection in humans and animals. As well, antibodies which specifically bind these compounds may be provided. Such antibodies and vaccines may be used to prevent or neutralize campylobacter infections in livestock thereby preventing this pathogen from entering the human food chain. The glycan may be linked to one or more amino acids to form a glycopeptide. As well, a method for determining the glycan structure of an intact glycoprotein consists of subjecting a sample to high resolution magic angle spinning nuclear magnetic resonance (HR-MAS-NMR) spectroscopy.
Owner:NAT RES COUNCIL OF CANADA
Loop-mediated isothermal amplication technology-based quick campylobacter jejunii detection kit and using method thereof
InactiveCN102121049AHigh sensitivityNot easy to polluteMicrobiological testing/measurementMicroorganism based processesManganeseBiology
The invention discloses a loop-mediated isothermal amplication technology-based quick campylobacter jejunii detection kit and a using method thereof. The kit consists of (1) reaction solution, (2) a primer group, (3) sample pretreatment solution and (4) positive contrast solution, wherein the primer group is one of the following eight primer groups, and each primer group comprises a pair of primers, namely an internal primer and an external primer; and a calcein manganese complex is added in advance in the reaction, the manganese is combined with pyrophosphate radical ions separated by dNTP to release the calcein, the released calcein can be observed and identified by naked eyes, the positive result is yellow green, and the negative result is light yellow. The kit has the advantages of strong specificity, short reaction time, high sensitivity and the like.
Owner:JIANGSU INST OF POULTRY SCI +2
Campylobacter jejuni outer membrane protein immunogenic composition
InactiveUS20050106159A1Reduce probabilityGenetic material ingredientsImmunoglobulins against bacteriaEpitopeCell Membrane Proteins
The field of this invention is the development of therapeutic agents having immunogenic efficacy against Campylobacter. The present invention is directed to a method of producing monoclonal antibodies that are highly specific for epitopes of Campylobacter jejuni outer membrane proteins; to specific monoclonal antibodies made by using the epitopes; and to uses thereof. The invention is drawn further to immunogens comprising certain outer membrane proteins or portions thereof from C. jejuni.
Owner:MEDICAL COLLEGE OF GEORGIA RES INST
Salmonella enterica presenting C. jejuni N-glycan or derivatives thereof
The present invention relates to Salmonella enterica comprising at least one pgl operon of Campylobacter jejuni or a functional derivative thereof and presenting at least one N-glycan of Campylobacter jejuni or N-glycan derivative thereof on its cell surface. In addition, it is directed to medical uses and pharmaceutical compositions thereof as well as methods for treating and / or preventing Campylobacter and optionally Salmonella infections and methods for producing these Salmonella strains.
Owner:ETH ZZURICH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com